Moving your cell therapy clinical trial beyond Phase I is an exciting time, marking a significant milestone. There are many therapeutic developers working to address critical patient needs in oncology, auto-immune, regenerative medicine, and other spaces. As all these programs move into late-stage clinical trials and commercialization is in reach, have you thought about the coming challenges to reach the market? Inefficient quality systems, lack of proper analytics, and inability to scale up and out your process can derail your hard work and stop your momentum in its tracks.
To avoid delays and added expense, it’s crucial to partner with a contract development and manufacturing organization (CDMO) with a history of both success and stability. With a legacy that spans over 75 years, Charles River is an established contract research organization (CRO) and CDMO that supports clients in all phases, from drug discovery and development through commercialization. Learn more about our Cell Therapy manufacturing capabilities.
Related Stories Gene Therapy Contract Development and Manufacturing: Challenges and Future Perspectives Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities Celebrating the Alderley Park Grand Opening Having gone through three successful audits for commercial cell therapies for both the US and Europe, you can depend on our regulatory expertise and global network of facilities to not only get you up and running for phase II and III t.